WO2009156466A1
|
|
Pharmaceutical compositions for the treatment of neurodegenerative diseases
|
WO2009109501A2
|
|
Ocular pharmaceutical compositions
|
WO2009037556A1
|
|
New agents for the treatment of the low urinary tract dysfunctions
|
WO2008146105A1
|
|
Prostaglandin pharmaceutical compositions
|
EP1980559A1
|
|
Cardiovascular agents
|
WO2006134489A1
|
|
Sulindac derivatives for treatment of cancer
|
WO2007019888A2
|
|
Therapeutic compositions containing mesalamine and a co-agent for treating colon diseases
|
EP1846401A1
|
|
New 4-aminoquinoline derivatives as antimalarials
|
EP1836160A1
|
|
Compounds for treating metabolic syndrome
|
US2009036516A1
|
|
Compounds for treating metabolic syndrome
|
US2009227597A1
|
|
Pyrazolopyrimidinones as phosphodiesterase inhibitors
|
WO2006111791A1
|
|
New anti-inflammatory compounds
|
EP1645288A1
|
|
New nuclear transcription factors regulators
|